FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323263365> ?p ?o ?g. }

• W4323263365 endingPage "2900.e10" @default.
• W4323263365 startingPage "2889" @default.
• W4323263365 abstract "Background & Aims There is an unmet need to validate simple and easily available methods that can be used in routine practice to identify those at risk of adverse outcomes from nonalcoholic fatty liver disease (NAFLD). A retrospective-prospective analysis of NAFLD patients enrolled in a longitudinal noninterventional study (TARGET-NASH) was performed to validate the prognostic utility of the following risk-categories: (A) Fibrosis-4 (FIB-4) <1.3 and/or liver-stiffness measurement (LSM) measured by Fibroscan <8 kp, (B) FIB-4 1.31‒2.6 and/or LSM 8.1-12.5 kp, and (C) FIB-4 >2.6 and/or LSM >12.5 kp. Methods Those in class A with aspartate transaminase:alanine transaminase ratio >1 or platelets <150,000/mm3, or class B with aspartate transaminase:alanine transaminase ratio >1 or platelets <150,000/mm3 were upstaged by one class. Fine-Gray competing risk analyses were performed for all outcomes. Results A total of 2523 individuals (class A = 555, B = 879, C = 1089) were followed for a median duration of 3.74 years. Adverse outcomes increased from class A to C in all-cause mortality (0.07 vs 0.3 vs 2.5/100 person-years [PY], hazard ratio [HR], 3.0 and 16.3 class B and C vs A), liver-associated clinical events (0.2 vs 1 vs 8/100 PY, HR, 4.3 and 36.6 B and C vs A), major adverse cardiovascular events (0.69 vs 0.87 vs 2.02/100 PY, HR, 0.78 and 1.55 B and C vs A), hepatocellular carcinoma (0 vs 0.09 vs 0.88/100 PY, HR, 8.32 C vs B), and chronic kidney disease (1.24 vs 2.48 vs 3.51/100 PY). Those who were upstaged had outcome rates similar to the lower class defined by their FIB-4. Conclusions These data support a FIB-4-based risk-stratification of NAFLD that can be used in routine clinical practice. ClinicalTrials.gov Identifier: NCT02815891 There is an unmet need to validate simple and easily available methods that can be used in routine practice to identify those at risk of adverse outcomes from nonalcoholic fatty liver disease (NAFLD). A retrospective-prospective analysis of NAFLD patients enrolled in a longitudinal noninterventional study (TARGET-NASH) was performed to validate the prognostic utility of the following risk-categories: (A) Fibrosis-4 (FIB-4) <1.3 and/or liver-stiffness measurement (LSM) measured by Fibroscan <8 kp, (B) FIB-4 1.31‒2.6 and/or LSM 8.1-12.5 kp, and (C) FIB-4 >2.6 and/or LSM >12.5 kp. Those in class A with aspartate transaminase:alanine transaminase ratio >1 or platelets <150,000/mm3, or class B with aspartate transaminase:alanine transaminase ratio >1 or platelets <150,000/mm3 were upstaged by one class. Fine-Gray competing risk analyses were performed for all outcomes. A total of 2523 individuals (class A = 555, B = 879, C = 1089) were followed for a median duration of 3.74 years. Adverse outcomes increased from class A to C in all-cause mortality (0.07 vs 0.3 vs 2.5/100 person-years [PY], hazard ratio [HR], 3.0 and 16.3 class B and C vs A), liver-associated clinical events (0.2 vs 1 vs 8/100 PY, HR, 4.3 and 36.6 B and C vs A), major adverse cardiovascular events (0.69 vs 0.87 vs 2.02/100 PY, HR, 0.78 and 1.55 B and C vs A), hepatocellular carcinoma (0 vs 0.09 vs 0.88/100 PY, HR, 8.32 C vs B), and chronic kidney disease (1.24 vs 2.48 vs 3.51/100 PY). Those who were upstaged had outcome rates similar to the lower class defined by their FIB-4. These data support a FIB-4-based risk-stratification of NAFLD that can be used in routine clinical practice." @default.
• W4323263365 created "2023-03-06" @default.
• W4323263365 creator A5014578938 @default.
• W4323263365 creator A5038073374 @default.
• W4323263365 creator A5040206411 @default.
• W4323263365 creator A5058087480 @default.
• W4323263365 creator A5059337045 @default.
• W4323263365 creator A5064131273 @default.
• W4323263365 creator A5070639714 @default.
• W4323263365 creator A5078309146 @default.
• W4323263365 creator A5079443276 @default.
• W4323263365 creator A5079537822 @default.
• W4323263365 creator A5086363081 @default.
• W4323263365 date "2023-10-01" @default.
• W4323263365 modified "2023-10-02" @default.
• W4323263365 title "Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort" @default.
• W4323263365 cites W2038981426 @default.
• W4323263365 cites W2054305537 @default.
• W4323263365 cites W2064387090 @default.
• W4323263365 cites W2081324449 @default.
• W4323263365 cites W2089535377 @default.
• W4323263365 cites W2110608362 @default.
• W4323263365 cites W2119415849 @default.
• W4323263365 cites W2129639561 @default.
• W4323263365 cites W2155965977 @default.
• W4323263365 cites W2204688218 @default.
• W4323263365 cites W2346887577 @default.
• W4323263365 cites W2739012525 @default.
• W4323263365 cites W2767268548 @default.
• W4323263365 cites W2800483138 @default.
• W4323263365 cites W2938096756 @default.
• W4323263365 cites W3003361050 @default.
• W4323263365 cites W3009945933 @default.
• W4323263365 cites W3012883032 @default.
• W4323263365 cites W3040545282 @default.
• W4323263365 cites W3137131423 @default.
• W4323263365 cites W3170703018 @default.
• W4323263365 cites W3206948891 @default.
• W4323263365 cites W4280552835 @default.
• W4323263365 cites W4294148126 @default.
• W4323263365 doi "https://doi.org/10.1016/j.cgh.2023.02.024" @default.
• W4323263365 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36871772" @default.
• W4323263365 hasPublicationYear "2023" @default.
• W4323263365 type Work @default.
• W4323263365 citedByCount "2" @default.
• W4323263365 countsByYear W43232633652023 @default.
• W4323263365 crossrefType "journal-article" @default.
• W4323263365 hasAuthorship W4323263365A5014578938 @default.
• W4323263365 hasAuthorship W4323263365A5038073374 @default.
• W4323263365 hasAuthorship W4323263365A5040206411 @default.
• W4323263365 hasAuthorship W4323263365A5058087480 @default.
• W4323263365 hasAuthorship W4323263365A5059337045 @default.
• W4323263365 hasAuthorship W4323263365A5064131273 @default.
• W4323263365 hasAuthorship W4323263365A5070639714 @default.
• W4323263365 hasAuthorship W4323263365A5078309146 @default.
• W4323263365 hasAuthorship W4323263365A5079443276 @default.
• W4323263365 hasAuthorship W4323263365A5079537822 @default.
• W4323263365 hasAuthorship W4323263365A5086363081 @default.
• W4323263365 hasConcept C126322002 @default.
• W4323263365 hasConcept C160160445 @default.
• W4323263365 hasConcept C181199279 @default.
• W4323263365 hasConcept C185592680 @default.
• W4323263365 hasConcept C188816634 @default.
• W4323263365 hasConcept C197934379 @default.
• W4323263365 hasConcept C207103383 @default.
• W4323263365 hasConcept C2776954865 @default.
• W4323263365 hasConcept C2778606649 @default.
• W4323263365 hasConcept C2778772119 @default.
• W4323263365 hasConcept C2779134260 @default.
• W4323263365 hasConcept C2779679107 @default.
• W4323263365 hasConcept C44249647 @default.
• W4323263365 hasConcept C55493867 @default.
• W4323263365 hasConcept C71924100 @default.
• W4323263365 hasConcept C90924648 @default.
• W4323263365 hasConceptScore W4323263365C126322002 @default.
• W4323263365 hasConceptScore W4323263365C160160445 @default.
• W4323263365 hasConceptScore W4323263365C181199279 @default.
• W4323263365 hasConceptScore W4323263365C185592680 @default.
• W4323263365 hasConceptScore W4323263365C188816634 @default.
• W4323263365 hasConceptScore W4323263365C197934379 @default.
• W4323263365 hasConceptScore W4323263365C207103383 @default.
• W4323263365 hasConceptScore W4323263365C2776954865 @default.
• W4323263365 hasConceptScore W4323263365C2778606649 @default.
• W4323263365 hasConceptScore W4323263365C2778772119 @default.
• W4323263365 hasConceptScore W4323263365C2779134260 @default.
• W4323263365 hasConceptScore W4323263365C2779679107 @default.
• W4323263365 hasConceptScore W4323263365C44249647 @default.
• W4323263365 hasConceptScore W4323263365C55493867 @default.
• W4323263365 hasConceptScore W4323263365C71924100 @default.
• W4323263365 hasConceptScore W4323263365C90924648 @default.
• W4323263365 hasFunder F4320332585 @default.
• W4323263365 hasIssue "11" @default.
• W4323263365 hasLocation W43232633651 @default.
• W4323263365 hasLocation W43232633652 @default.
• W4323263365 hasOpenAccess W4323263365 @default.
• W4323263365 hasPrimaryLocation W43232633651 @default.
• W4323263365 hasRelatedWork W2034624443 @default.
• W4323263365 hasRelatedWork W2058103134 @default.

• next